What are GH secretagogue research peptides?
GH secretagogues are synthetic peptides studied in research for their activity at receptors involved in growth hormone signaling cascades. As a compound class, they do not constitute a homogeneous group. They share a functional research framing — activity at receptors upstream of pituitary GH output — but the two principal subclasses engage entirely distinct receptor targets through distinct structural mechanisms. Understanding the distinction is foundational to research design.
The term "secretagogue" in the peptide research context encompasses two receptor systems: the growth hormone-releasing hormone (GHRH) receptor, activated by GHRH analogs, and the ghrelin receptor (GHS-R1a), activated by growth hormone-releasing peptides (GHRPs) and related synthetic agonists. Both receptor systems are studied for their roles in GH signaling, but the downstream pharmacology, signaling cascades, and receptor interaction profiles differ meaningfully between them. AminoLine catalogs compounds from both subclasses, all intended for laboratory research use only and not for human use.
What are the two principal receptor classes in this category?
The GH secretagogue research category divides into GHRH receptor agonists and ghrelin receptor agonists. The distinction is not semantic — it determines the receptor being studied, the associated signal transduction pathway, and how results should be interpreted relative to the broader GH signaling literature.
GHRH receptor agonists. These compounds are synthetic analogs of native growth hormone-releasing hormone, a 44-amino-acid hypothalamic peptide. GHRH receptor agonists studied in research include CJC No DAC, Sermorelin Acetate, and Tesamorelin. Each is based on the 29-amino-acid bioactive region of native GHRH and interacts with the GHRH receptor, a class B G-protein-coupled receptor. Research in this subclass focuses on characterizing GHRH receptor binding affinity, cAMP-mediated signal transduction, and the pharmacokinetic differences introduced by structural modifications across analogs.
Ghrelin receptor agonists. These compounds — including Ipamorelin, Hexarelin, and GHRP-2 — engage the GHS-R1a receptor through a structurally distinct mechanism. The GHS-R1a receptor is a class A GPCR studied for its role in GH pulse regulation, appetite signaling research, and energy homeostasis pathways. Ghrelin receptor agonists are studied for their receptor selectivity profiles and the degree to which they activate the GHS-R1a axis without engaging adjacent signaling systems.
Grouping both subclasses under "GH secretagogues" is a research convenience, not a mechanistic equivalence.
How are GHRH receptor agonists characterized in research?
GHRH receptor agonist research focuses on three primary variables: binding affinity at the GHRH receptor, stability in the experimental model system, and the pharmacokinetic profile introduced by structural modifications to the native GHRH sequence. Native GHRH(1-44) is studied as the reference ligand, but it carries a short half-life in aqueous systems due to enzymatic cleavage at the N-terminus by dipeptidyl peptidase IV (DPP-IV). Synthetic analogs are designed to characterize how structural modifications alter this profile.
CJC No DAC is the most studied example of a structurally minimal GHRH analog — a 29-amino-acid sequence corresponding to GHRH(1-29) without a drug affinity complex attached. It is studied as a shorter-half-life reference point for GHRH receptor activity. Sermorelin Acetate represents a related structural class, also based on the GHRH(1-29) region. Tesamorelin incorporates an N-terminal trans-3-hexenoic acid modification studied for its effect on DPP-IV resistance.
In research design, the analog chosen determines the kinetic window being examined. Short-half-life analogs like CJC No DAC are used to study pulsatile receptor activation, while longer-acting structural variants introduce different temporal signaling dynamics. These distinctions matter when comparing results across the GHRH analog literature.
How are ghrelin receptor agonists characterized in research?
Ghrelin receptor agonists are characterized by their binding selectivity at the GHS-R1a receptor and the degree to which they activate downstream signaling through a distinct pathway from GHRH receptor agonists. Ghrelin itself is a 28-amino-acid acylated peptide that functions as the endogenous GHS-R1a ligand. Synthetic ghrelin receptor agonists are studied as structural analogs that bind the same receptor with varying degrees of selectivity.
Ipamorelin is the most widely studied selective ghrelin receptor agonist in the current research compound catalog. Its selectivity profile — high affinity for GHS-R1a with limited engagement of adjacent receptors — makes it a reference compound in studies examining isolated ghrelin receptor signaling. Earlier-generation ghrelin receptor agonists such as GHRP-2 and Hexarelin are studied for their broader engagement profiles, which include interactions with receptors beyond GHS-R1a, making them less selective probes for the isolated ghrelin receptor pathway.
Research on ghrelin receptor agonists spans several signaling contexts: GH pulse regulation in somatotroph models, orexigenic signaling pathways, and in some experimental models, cardiovascular receptor expression. Compound selection depends on whether researchers require a selective probe or a broader agonist profile for their experimental question.
Why are GHRH and ghrelin receptor agonists studied in combination?
Because GHRH receptor agonists and ghrelin receptor agonists engage distinct, non-redundant signaling axes, their combinatorial study is a recognized approach to characterizing how the two systems interact at the level of GH signaling output. The GH axis has at least two independently regulatable input signals — GHRH-driven cAMP signaling and ghrelin-driven calcium mobilization — and research examining both in the same experimental system is designed to understand the interaction between these pathways.
AminoLine catalogs a CJC/IPA blend for research applications that require both components in the same preparation. The blend is supplied at defined per-component concentrations and is intended for studies where researchers are examining the combinatorial receptor signaling profile rather than isolating a single pathway. Researchers designing studies for individual pathway characterization should use CJC No DAC and Ipamorelin as separate compounds.
The rationale for combinatorial research does not imply that the two compounds are interchangeable or that their combination produces outcomes not attributable to each receptor system. Characterizing the signaling interaction requires understanding each component first, which is why the single-compound literature is foundational to interpreting blend studies correctly.
What quality standards apply to GH secretagogue compounds?
GH secretagogue peptides share the same fundamental quality requirements as other research-grade peptides, with some category-specific considerations. GHRH analogs are particularly sensitive to N-terminal degradation — the same DPP-IV cleavage that defines their research profile also operates under suboptimal storage conditions. For research to be reproducible, the compound received must match the structural specification at the point of use, not only at the point of manufacture.
Minimum quality requirements for this category: HPLC-verified purity with the chromatogram available on request, mass spectrometry identity confirmation, a batch-specific Certificate of Analysis rather than a generic reused document, endotoxin testing for compounds used in cell culture, and cold-chain shipping as standard rather than optional. A compound with a stated purity of 99% that was shipped at ambient temperature through an extended warm-weather transit cannot be treated as meeting that specification upon arrival.
The 2025-2026 period of vendor closures and enforcement actions produced documented evidence of substandard GH secretagogue batches circulating in the research market. Independent third-party testing identified mislabeled and substandard CJC-1295 preparations. The lesson for researchers is that supplier documentation should be evaluated on its specificity — batch numbers, testing dates, testing laboratory identity — not on the presence of paperwork alone.
How does AminoLine source GH secretagogue compounds?
AminoLine supplies GHRH receptor agonists and ghrelin receptor agonists as research-grade compounds characterized by independent third-party analytical testing. All GH secretagogue compounds in the catalog — including CJC No DAC, Sermorelin Acetate, Tesamorelin, Ipamorelin, and the CJC/IPA blend — are held to purity specifications verified by HPLC, with mass spectrometry identity confirmation and batch-specific COAs included with every order.
All shipments are cold-chain packaged to protect peptide structural integrity in transit. Operations are US-based. Researchers can review the full GH secretagogue catalog, specifications, and available sizes at all compounds. For compound-level detail on the GHRH analog at the center of this category, see CJC No DAC: Molecular Structure, GHRH Receptor Pharmacology, and Research Overview. All material is intended for laboratory research use only and is not for human use.
All compounds referenced in this article are research chemicals intended for laboratory and scientific research purposes only. They are not drugs, supplements, or food products, and are not intended to diagnose, treat, cure, or prevent any disease. AminoLine does not sell products intended for human use. Researchers are responsible for compliance with all applicable local, state, and federal regulations governing the purchase and use of research materials.